Frenelle Private Investor Briefing - Tysons Corner

​Dear Investors,

​Frenelle Pharma is developing next-generation long-acting injectable therapeutics using its proprietary Faros™ drug-delivery platform. Its lead program, FRN01, is a 30-day subcutaneous buprenorphine injection being developed for Opioid Use Disorder (OUD).

​Join Opus8 and New York Private Equity Forums (NYPEF) for an exclusive investor briefing to learn more about Frenelle’s differentiated approach, development progress, and investment opportunity.

​Why Investors Are Taking Notice

​Large, Underpenetrated Market — The global long-acting injectable buprenorphine market exceeded $1.2B in 2025, yet reaches less than 10% of patients treated for OUD.

​Differentiated Product — FRN01 is designed to provide monthly treatment while addressing key patient and access barriers.

​Validated Technology — Frenelle’s Faros™ platform has been clinically validated, with FRN01 demonstrating formulation proof of concept.

​Near-Term Milestones — Frenelle is advancing formulation optimization, IND-enabling studies, and an FDA pre-IND meeting.

​Event Details:

​Date: October 6
Time: 5:30 PM EDT
Location: Tysons Corner, VA

​Please note that this meeting is for DIRECT and ACTIVE Accredited investors only. All RSVPs are subject to review and approval.

​Request investor materials by contacting Skylar Rallison at srallison@opus8.com.

​Thanks much and all the best,

​Tien Wong
CEO
Opus8, Inc.